The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines

Concetta Paola Ilisso, Maria Castellano, Silvia Zappavigna, Angela Lombardi, Giovanni Vitale, Alessandra Dicitore, Giovanna Cacciapuoti, Michele Caraglia, Marina Porcelli

Research output: Contribution to journalArticlepeer-review

Abstract

In this work, we have investigated the antiproliferative effect of AdoMet and Doxorubicin (Doxo), alone or in combination, on different breast cancer cell lines. For the evaluation of synergism, we have calculated the combination index (CI) by the Calcusyn software and we have evaluated the effects of the combination on apoptosis occurrence at FACS analysis in hormone-dependent CG5 cell line. We have found that AdoMet and Doxo given in combination were strongly synergistic in the hormone-dependent CG5 and MCF-7 human breast cancer cell line, as a CI50 

Original languageEnglish
Pages (from-to)212-222
Number of pages11
JournalEndocrine
Volume50
Issue number1
DOIs
Publication statusPublished - Sep 25 2015

Keywords

  • Cytotoxicity
  • Doxorubicin
  • Drug combination
  • Hormone-dependent breast cancer cell line CG5
  • S-adenosylmethionine

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines'. Together they form a unique fingerprint.

Cite this